Nothing Special   »   [go: up one dir, main page]

Winnie et al., 1989 - Google Patents

Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis

Winnie et al., 1989

Document ID
8202478771950465159
Author
Winnie G
Cowan R
Wade N
Publication year
Publication venue
The Journal of pediatrics

External Links

Snippet

The effect of intravenously administered immune globulin (IVIG) on patients with cystic fibrosis with an acute exacerbation of pulmonary infection was evaluated in a double-blind study. Patients at least 12 years of age, with chronic respiratory tract colonization with …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Similar Documents

Publication Publication Date Title
Winnie et al. Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis
AMENT et al. Structure and function of the gastrointestinal tract in primary immunodeficiency syndromes a study of 39 patients
Warren et al. Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor
Navasa et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality
Ordoñez et al. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study
Weisman et al. Intravenous immune globulin therapy for early-onset sepsis in premature neonates
WO1991004054A1 (en) Treatment of ards
Dunn Gram-negative bacterial sepsis and sepsis syndrome
JPH02283294A (en) Human monoclonal antibody
Matzneller et al. Colistin reduces LPS‐triggered inflammation in a human sepsis model in vivo: a randomized controlled trial
Pennington et al. Concentrations of gentamicin and carbenicillin in bronchial secretions
Currie et al. Double blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis
Lang et al. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis
Bingen et al. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation
FI94489C (en) Process for Preparation of Cross-Protecting Human Monoclonal Antibodies and a Cell Line Producing the Antibodies
Held et al. Granulocyte colony-stimulating factor worsens the outcome of experimental Klebsiella pneumoniae pneumonia through direct interaction with the bacteria
Landesman et al. Infections in children with sickle cell anemia Special reference to pneumococcal and salmonella infections
Endo et al. Experimental immunoglobulin A nephropathy induced by gram-negative bacteria
Höpfner et al. Yersinia enterocolitica infection with multiple liver abscesses uncovering a primary hemochromatosis
Warny et al. Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A
Moss et al. 125I-Clq-binding and specific antibodies as indicators of pulmonary disease activity in cystic fibrosis
Garside et al. Immunoglobulin and IgG subclass levels in a regional pediatric cystic fibrosis clinic
Cross et al. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects
ANDERSSON et al. Gamma-globulin treatment of recurrent acute otitis media in children
Ciofu et al. Antibodies against β‐lactamase can improve ceftazidime treatment of lung infection with β‐lactam‐resistant Pseudomonas aeruginosa in a rat model of chronic lung infection